We are live on ! Find out more
LJPC

La Jolla Pharmaceutical Company

Delisted

LJPC was delisted on the 19th of August, 2022.

62 hedge funds and large institutions have $279M invested in La Jolla Pharmaceutical Company in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 25 increasing their positions, 18 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

116% more call options, than puts

Call options by funds: $4.59M | Put options by funds: $2.13M

39% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 18

13% less funds holding

Funds holding: 7162 (-9)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

27% less capital invested

Capital invested by funds: $382M → $279M (-$103M)

62% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 13

Holders
62
Holders Change
-9
Holders Change %
-12.68%
% of All Funds
1.55%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
5
Increased
25
Reduced
18
Closed
13
Calls
$4.59M
Puts
$2.13M
Net Calls
+$2.46M
Net Calls Change
-$4.38M
Name Holding Trade Value Shares
Change
Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$666K +$14.3K +744 +2%
California Public Employees Retirement System
27
California Public Employees Retirement System
California
$654K
Bank of America
28
Bank of America
North Carolina
$528K +$23.8K +1,239 +4%
California State Teachers Retirement System (CalSTRS)
29
California State Teachers Retirement System (CalSTRS)
California
$503K -$13.4K -700 -2%
CFIC
30
City Financial Investment Company
United Kingdom
$494K +$540K +28,188 New
TA
31
Teachers Advisors
New York
$445K +$53.5K +2,791 +12%
Swiss National Bank
32
Swiss National Bank
Switzerland
$428K
HCM
33
Hollencrest Capital Management
California
$387K
Charles Schwab
34
Charles Schwab
California
$379K
Susquehanna International Group
35
Susquehanna International Group
Pennsylvania
$358K +$42.3K +2,206 +12%
NPC
36
National Planning Corporation
California
$341K
RhumbLine Advisers
37
RhumbLine Advisers
Massachusetts
$260K +$19.6K +1,025 +7%
VEA
38
Virtus ETF Advisers
New York
$251K +$728 +38 +0.3%
Wells Fargo
39
Wells Fargo
California
$244K -$41.5K -2,163 -13%
BBA
40
Baker Bros. Advisors
New York
$241K
New York State Common Retirement Fund
41
New York State Common Retirement Fund
New York
$238K
AllianceBernstein
42
AllianceBernstein
Tennessee
$223K
Manulife (Manufacturers Life Insurance)
43
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$175K +$2.43K +127 +1%
MLICM
44
Metropolitan Life Insurance Company (MetLife)
New York
$167K -$73.4K -3,829 -29%
NFA
45
Nationwide Fund Advisors
Ohio
$161K
UBS Group
46
UBS Group
Switzerland
$141K -$45.9K -2,395 -23%
AIG
47
American International Group
New York
$140K -$422 -22 -0.3%
BA
48
BlackRock Advisors
Delaware
$122K -$4.43K -231 -3%
CG
49
Cutler Group
California
$79K -$70.3K -3,668 -45%
BG
50
BlackRock Group
United Kingdom
$76K +$10.9K +567 +15%

LJPC Hedge Fund Activity: Q4 2016 in Review

62 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q4 2016, worth a combined $279M — down 27% from $382M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of LJPC and 5 opened new positions — a net loss of 8 holders — while 18 trimmed existing stakes and 25 added.

The largest buyer was Sabby Management, adding an estimated $1.73M. The largest seller was Asset Management One, exiting entirely with an estimated $3.07M sold.

  • 62 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q4 2016, down from 71 in Q3 2016.
  • Funds reported $279M of La Jolla Pharmaceutical Company stock for Q4 2016, down 27% quarter-over-quarter.
  • 5 funds opened new La Jolla Pharmaceutical Company positions in Q4 2016 and 13 closed out, a net change of -8 holders.
  • The largest La Jolla Pharmaceutical Company buyer in Q4 2016 was Sabby Management, an estimated $1.73M added.
  • The largest La Jolla Pharmaceutical Company seller in Q4 2016 was Asset Management One, an estimated $3.07M sold.

Based on aggregated 13F filings for Q4 2016.